Dear SMA Community,
We want to provide an update on Biogen’s efforts to help ensure the health and safety of the SMA community amid the novel Coronavirus (COVID-19).
As you may have heard, on February 26-27, Biogen held a strategic management meeting in Boston with primarily office-based employees. Following the meeting, several attendees developed flu-like symptoms and tested positive for COVID-19.
In response, anyone who attended the meeting has been in self-quarantine as of March 4. Additionally, individuals who tested positive for COVID-19 are in isolation. All office-based employees in our Massachusetts, Washington, DC and Raleigh, North Carolina offices are working from home until further notice. We also made the decision to hold all Biogen patient programs virtually in March.
Biogen SMA Family Access Managers (FAMs) and Account Executives will continue to support the SMA community and be available for in-person meetings as needed and requested. If you do not feel comfortable meeting in person, our Patient Services team is also available virtually to support patients and families who need it.
As some families have asked, we want to share that we do not expect any impact to the safety of our supply of SPINRAZA. We also do not expect a shortage to the availability of SPINRAZA.
Thank you for your understanding and collaboration. We will update you further as new information becomes available. In the meantime, please don’t hesitate to contact us with any questions or concerns.
The Biogen SMA Team